Oaktree Acquisition Corp. III Life Sciences
For the period ended Dec 31, 2024. Filed Mar 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 27, 2025
OACC$10.70-0.2%Stored close · as of Nov 5, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheet
| ASSETS | |
|---|---|
| Current assets | |
| Cash | $1,357,044 |
| Prepaid expenses | 201,281 |
| Total current assets | 1,558,325 |
| Long Term prepaid insurance | 113,275 |
| Cash held in Trust Account | 193,579,022 |
| TOTAL ASSETS | $195,250,622 |
| LIABILITIES AND SHAREHOLDERS’ DEFICIT | |
| Current liabilities | |
| Accrued expenses | $535,515 |
| Accrued offering costs | 179,984 |
| Promissory note - related party | 11,824 |
| Total current liabilities | 727,323 |
| Deferred legal fee | 299,088 |
| Deferred underwriting fee payable | 6,719,660 |
| TOTAL LIABILITIES | 7,746,071 |
| Commitments and Contingencies | |
| Class A ordinary shares subject to possible redemption, at redemption value of $10.08 per share, 19,199,029 issued and outstanding | 193,579,022 |
| Shareholders’ Deficit | |
| Preference shares, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding | — |
| Class A ordinary shares, $0.0001 par value; 300,000,000 shares authorized; 583,981 issued and outstanding (excluding 19,199,029 shares subject to possible redemption) | 58 |
| Class B ordinary shares, $0.0001 par value; 30,000,000 shares authorized; 4,799,758 shares issued and outstanding | 480 |
| Additional paid-in capital | — |
| Accumulated deficit | (6,075,009) |
| TOTAL SHAREHOLDERS’ DEFICIT | (6,074,471) |
| TOTAL LIABILITIES AND SHAREHOLDERS’ DEFICIT | $195,250,622 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.